SVB Wealth LLC Makes New $5.04 Million Investment in IQVIA Holdings Inc. (NYSE:IQV)

SVB Wealth LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 25,659 shares of the medical research company's stock, valued at approximately $5,042,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IQV. Smith Group Asset Management LLC acquired a new position in IQVIA in the 4th quarter worth about $1,616,000. Simplify Asset Management Inc. increased its stake in shares of IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock valued at $2,284,000 after buying an additional 3,894 shares during the period. Nordea Investment Management AB raised its holdings in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. acquired a new stake in IQVIA during the 4th quarter worth approximately $941,000. Finally, Fifth Third Bancorp raised its stake in shares of IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after acquiring an additional 1,521 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Up 1.3 %

NYSE IQV traded up $2.47 on Wednesday, hitting $186.04. 1,050,048 shares of the stock were exchanged, compared to its average volume of 1,208,520. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $261.73. The stock has a fifty day moving average price of $198.24 and a two-hundred day moving average price of $213.66. The firm has a market capitalization of $32.80 billion, a P/E ratio of 24.81, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. Barclays reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd. Leerink Partners reissued an "outperform" rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. StockNews.com upgraded IQVIA from a "hold" rating to a "buy" rating in a report on Tuesday. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Finally, Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.